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Abstract
Glioblastoma is a fatal brain cancer with low median and yearly survival rates. The standard of 
care for treating glioblastoma is gross total resection (GTR) coupled with the Stupp protocol, but 
various factors influence the interventions undertaken and survival achieved. As health disparities 
exist in rural areas, survival in these areas need to be assessed in order to understand which factors 
detract from the successes of these standard medical interventions. We retrospectively determined 
the impact of age of diagnosis, number of lesions, the molecular marker O6-methylguanine 
methyltransferase (MGMT), extent of surgery, and completion of the Stupp protocol on survival 
among patients treated at West Virginia University Hospitals. We found that an age of diagnosis 
under 60 years, having the MGMT gene methylated, having a unifocal tumor, receiving GTR, 
adhering to the Stupp protocol, and undergoing a treatment course of GTR followed by the Stupp 
protocol significantly increased survival. Lastly, we compared our findings to a pre-Stupp study 
done in West Virginia in 1996. This comparison showed that although overall median survival has 
not increased, all interventions involving GTR have resulted in a significantly higher survival. We 
conclude that we can serve our patient population by offering GTR to all adult glioblastoma 
patients when no contraindications exist and ensuring that patients follow the Stupp protocol. 
After discharge, the Stupp protocol may not be followed/completed for a variety of reasons. In the 
future, we aim to assess these reasons and analyze other significant interventional and 
socioeconomic factors which influence survival.
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Introduction
Glioblastoma, an aggressive glial tumor, is the most prevalent brain tumor in adults and 
usually occurs in middle-aged patients. On imaging, these tumors appear as contrast 
enhancing masses, sometimes with a butterfly pattern that can often extend across the corpus 
callosum. Microscopically, the tumors have central areas of necrosis and hemorrhage 
surrounded by pseudopalisading cells. Median survival for adults with glioblastoma who 
undergo appropriate therapy has been reported to be 14.6 months while 2-year survival is 
26.5%27; patients surviving beyond 36 months are known as long-term survivors. Prognostic 
indicators of increased survival time are young age, having a single tumor, O6-
methylguanine methyltransferase (MGMT) methylation, gross total resection (GTR) of the 
presenting lesion, and post-operative completion of the Stupp protocol.
The Stupp protocol calls for the use of 60Gy radiotherapy concurrently with temozolomide 
(TMZ) over 6 weeks after tumor resection, followed by six 28-day cycles of TMZ alone. 
The success of this protocol is linked to MGMT methylation as MGMT expression causes 
tumor resistance to alkylating chemotherapeutic agents such as TMZ and nitrosureas. When 
this gene is silenced (methylated), the tumor’s DNA repair is impaired and chemotherapy 
becomes more effective, especially when combined with radiation9. This observation that 
the prognostic value of MGMT methylation is dependent on treatment modality builds upon 
the Stupp findings27. MGMT methylation has also been linked to long-term survival26.
West Virginia, a mostly rural state5 in the Appalachian region which is medically 
underserved and economically disadvantaged3, is known to have many negative health 
outcome metrics. These include a high overall cancer prevalence relative to the U.S’ 
median12, as well as a high cancer mortality of 223.9/100000 people and high rates of 
obesity (35.6%) and diabetes (14.5%)2. These statistics earned West Virginia ranks of 48, 
47, and 49, relative to other states2. Furthermore, West Virginia also rates below the median 
of the U.S. regarding the social determinants of health such as education and income2, which 
have been identified as primary influences driving disparities in cancer morbidity and 
mortality11. These statistics indicate that there are underlying sociodemographic issues that 
detract from the benefit patients may otherwise experience from a medical intervention.
The Appalachian region’s health disparities have impacted the cancer morbidity and 
mortality for this population. Although cancer rates have declined in the U.S.25, this decline 
has been lower in Appalachia31, with the incidence of cancer being higher in Appalachia 
than the U.S. in general29. It has been shown that although mortality rates have decreased by 
22% in the U.S in general from 1990–2001, rural Appalachia has only experienced a decline 
of 12%30. Across the entire U.S, the incidence of cancer was shown to increase only in rural 
Appalachia between 2007 and 201130.
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A pre-Stupp study by Jubilirer in 1996 at Charleston Area Medical Center (CAMC) in West 
Virginia found that a younger age at diagnosis (<40) and radiotherapy (albeit of varying 
doses) were the best predictors of survival in 138 patients16, a result which has been verified 
by other studies8,18. However, due to both tumor (e.g. location) and patient characteristics 
such as comorbidities, this approach is not always practical. The impact on survival of 
implementing the Stupp protocol in an Appalachian hospital is unknown but could be 
important in standardizing and optimizing treatment practices and delivery of care in West 
Virginia and Appalachia in general, especially in light of the state’s poor health metrics. We 
analyzed data from 243 glioblastoma patients from 2009-present to determine patient 
demographics and survival, tumor characteristics, and courses of treatment. We then used 
multivariate analyses to determine which combination of these factors yielded the greatest 
survival in our patients. As our institution serves a mostly rural population with its own 
health disparities, we hypothesized that our population would show an overall median 
survival less than that shown by Stupp et al27 but that the reported indicators of increased 
survival will also serve as good prognostic indicators in out patient population. This research 
serves as a springboard for finding deficiencies in glioblastoma care and identifying ways to 
ameliorate those deficiencies in economically disadvantaged rural communities.
Methods
Study Approval
This retrospective cohort study was approved by the WVU Office of Research Integrity and 
Compliance.
Study Design
The information for this study was gleaned from West Virginia University Hospital’s 
(WVUH) electronic medical record as well as other hospitals’ records when needed. Our 
data came from 243 living and deceased patients and consisted of 96 females (39.5%) and 
147 males (60.5%) ranging between the ages of 20–88 at diagnosis. Only newly diagnosed 
cases with a definitive pathologic diagnosis of glioblastoma were included. These diagnoses 
were made by a neuro-pathologist who was at our institution for the entire period we 
reviewed in this study. Most resections done at our institution (89%) were done by four 
surgeons, whose techniques were tailored largely to the tumor’s location. Although all 
surgeries used pre-operative imaging, post-operative imaging was not done in all cases. One 
surgeon frequently used fluorescein staining during his procedures.
Procedure
Demographical information collected included name; date of birth; age at diagnosis; and 
survival from diagnosis until death, or present if they were still alive. Patient identifying 
information was used only for the purpose of collating information. Overall survival was 
calculated from the diagnosis of glioblastoma, even if lower grade tumors were present 
before this diagnosis. The prognostic factors we looked at individually as independent 
variables were:
• age (below 60 years, 60 years and above)
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• MGMT gene methylation status (positive, negative)
• number of tumors at presentation (unifocal, multifocal)
• surgical intervention (GTR, subtotal resection (STR), or biopsy)
• completion of the Stupp protocol (full, incomplete, none)
The determination of GTR versus STR was made using Brainlab software to calculate tumor 
volumes before and after surgery. Using this software, our criteria for GTR was a resection 
of 98% or greater while STR was defined as being below 98% of the tumor volume, based 
on one of the earlier papers that evaluated a threshold for a beneficial extent of resection and 
found that removing ≥98% of the tumor had the greatest effect on increasing survival17. We 
calculated survival due to the surgical intervention from the date of the initial resection/
biopsy. In cases where a biopsy preceded a resection by less than two months, we counted 
the resection as the intervention as patients may have received a biopsy to assess the need for 
– and extent of – resection. In all analyses that involve a surgical intervention, the 
denominator we used was the total number of patients that received any surgical 
intervention.
Due to clinical patient considerations, we considered a complete dose of radiation as being 
54-63Gy. 13 patients died before chemoradiation was discussed or begun and were excluded 
from our study. As radiation could start at various time points after a resection/biopsy and 
last for various periods, the survival data for assessing the effect of completion of the Stupp 
protocol were corrected to start from the mid-point of the course of concurrent 
chemoradiation.
In order to reflect the impact of the standard clinical management of glioblastoma, we then 
sought to discover the survival impact of undergoing the standard course of treatment. For 
this, we considered the surgical intervention they underwent and their completion of the 
Stupp protocol. In doing so, we derived the following groups:
• GTR with completion of the Stupp protocol
• STR with completion of the Stupp protocol
• Biopsy
Lastly, in order to assess how the impact of implementing the Stupp protocol in West 
Virginia, we compared our results to those of Jubilirer (1996), taking care to compare the 
groups in his study to equivalent groups in ours that reflect the standard of care.
Statistical analysis
With survival as an endpoint, we calculated median survival, with standard error (SE) and 
95% confidence intervals (CI) using the formulas below, for the above prognostic factors. 
The standard error formula was adjusted for the use of median values by multiplying by 
1.253. A Moods test in XLSTAT (Addinsoft) with multiple pairwise comparisons set to give 
exact p-values was used to evaluate for significance among the medians of the groups into 
which the prognostic factors were divided. Pairwise testing was used as the groups under 
each prognostic factor (or combination of) carry their own clinical weight. α was set at 0.05 
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for all these conditions. Kaplan-Meier curves were also made in XLSTAT for the groups of 
each prognostic factor. These curves were used to compare the number of patients alive after 
1 year. We used a log rank test to evaluate for significance among the curves.
In comparing our date to that of Jubelirer’s, we calculated the percentage of people who had 
undergone a specific intervention by setting the denominator to be the number of patients 
that had received any surgical intervention (including a biopsy). Lastly, we calculated the 





2 th ranked value
CI upper limit
1 + n2 +
1.96 n
2 th ranked value
Results
Age and survival
The majority of our patients were above 60 years old when initially diagnosed (Table 1) with 
the median age at diagnosis in our patient population being 63.5 years (Table 2). Our patient 
population had a median survival of 7 months (SE ± 1.3) with 18 people who had survived 
longer than 36 months (long-term survivors), most of whom were under 60 years at the time 
of diagnosis (see tables). The group of patients who were below 60 years at diagnosis had a 
higher median survival of 14 months (SE ± 2.5; 95% CI: 11–18); the group of patients above 
60 years at the time of diagnosis had a median survival of 4 months (SE ± 1.2; 95% CI: 3–5) 
(Figure 1). A Moods test showed that these results were significantly different (p<0.0001).
The 1-year survival in the group of patients who were below 60 at the time of diagnosis was 
55% while that in the group of patients above 60 at the time of diagnosis was 21% (Figure 
2). A log-rank test showed that the survival distribution of these groups over time were 
significantly different (p<0.0001).
Tumor characteristics and survival
The molecular marker tested most frequently was MGMT, albeit tested in less than 50% of 
initial cases – the gene was found to be methylated (MGMT+) in 37% of patients tested. We 
found that the MGMT+ group had a median survival of 14 months (SE ± 3.0; 95% CI: 8–22) 
while that of the MGMT- group was 7 months (SE ± 2.4; 95% CI: 4–11) (Figure 1). A 
Moods test showed that these values were significantly different (p=0.021). The MGMT+ 
group had a 1-year survival of 49% while the MGMT- group had a 1-year survival of 29% 
(Figure 2). A log-rank test showed that the survival distribution of these groups over time 
were not significantly different (p=0.069).
Most of our patients had unifocal tumors at presentation, mostly in the frontal lobe. Most 
multifocal tumors also involved the frontal lobe. The groups with unifocal tumors at 
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presentation had a median survival of 8.5 months (SE ± 1.5; 95% CI: 6–10) while this was 4 
months (SE ± 2.4; 95% CI: 2–9) in the group with multifocal tumors (Figure 1). A Mood’s 
test showed that these values were significantly different (p=0.010). The group with a 
unifocal tumor at presentation had a 1-year survival of 36% while the group with multifocal 
tumors showed a 1-year survival of 24% (Figure 2). A log-rank test showed that the survival 
distribution of these groups over time were significantly different (p=0.023).
Individual interventions and survival
Most of our patients received a resection at WVUH as part of their treatment, with 41 
patients having both a biopsy and a resection – in such cases, the biopsy was used to 
determine a diagnosis and/or assess the need for resection. Of all patients that had a 
resection, 50 were scheduled for a re-resection either due to incomplete resection or 
recurrence (Table 1). Here, we only include results for those patients whose pre- and post-
operative scans we had, from which we were able to assess an accurate extent of resection.
The group that received GTR had the longest median survival of 15 months (SE ± 6.6; 95% 
CI: 12–24). The group that received STR had a median survival of 10 months (SE ± 7.8; 
95% CI: 3–15) while the group that received a biopsy had a median survival of 3 months 
(SE ± 0.8; 95% CI: 2–4) (Figure 1). A Moods test showed a significant difference in survival 
between only the groups that received GTR and biopsy (p<0.0001). The group that received 
GTR had the highest 1-year survival of 64%. The 1-year survival with the group that 
received STR was 41%, while that for the group with a biopsy was 10% (Figure 2). A log-
rank test showed that the survival distribution of these groups over time were significantly 
different (p<0.0001).
Among the patients for whom we had definitive information, most of those who underwent 
radiation completed treatment as per the Stupp protocol. The group that completed the Stupp 
protocol had a median survival of 16 months (SE ± 3.3; 95% CI: 13–20), the group that did 
not undergo this treatment had a median survival of 3 months (SE ± 2.4; 95% CI: 1–5), 
while the group that did not complete this treatment had a median survival of 2 months (SE 
± 0.6; 95% CI: 1–3) (Figure 1). A Moods test showed that the result for the group that 
completed the Stupp protocol differed significantly from both the group that did not undergo 
(p=0.0004) or not complete this treatment (p<0.0001). The group that completed the Stupp 
protocol had a 1-year survival of 66%. The group that did not undergo this treatment had a 
1-year survival of 12%, while the group that did not complete this treatment had a 1-year 
survival of 0% (Figure 2). A log-rank test showed that the survival distribution of these 
groups over time were significantly different (p<0.0001).
Treatment course and survival
The group that had received GTR with completion of the Stupp protocol showed the greatest 
median survival of 23.5 months (SE ± 7.1; 95% CI: 13–34) and 1-year survival of 87%. The 
group that received STR with completion of the Stupp protocol had a median survival of 14 
months (SE and 95% CI could not be calculated) with a 1-year survival of 63% (see figures). 
A Moods test showed a significant difference in median survival between those that received 
GTR and completed the Stupp protocol and those that received a biopsy (p<0.0001). A log-
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rank test showed that the survival distribution of these groups over time were significantly 
different (p<0.0001).
Comparison to previous West Virginia study
We compared the treatment groups in the Jubilirer 1996 study to equivalent groups in ours. 
Overall median survival, survival with STR, and survival with STR and radiation therapy 
(RT; for which the equivalent in our study is completion of the Stupp protocol) were similar 
between our studies. The percentage of patients receiving GTR alone, GTR and RT, STR 
alone, and STR and RT were all decreased in our study. Lastly, the survival with GTR, 
survival with GTR and RT, percentage receiving biopsy, percentage receiving RT, and 1st 
and 2nd year survival were all increased in our study (Table 2). For the purposes of this table, 
biopsies were only considered when comparing surgical interventions and were not part of 
the comparison for the treatment courses. Survival with the treatment courses and percentage 
receiving RT are given as a percentage of all patients that received resection.
Discussion
As age, MGMT gene methylation, tumor burden, extent of resection, and the Stupp protocol 
have all been linked to survival in other studies, we performed this study to determine the 
impact these prognostic factors have on our patient population as a way of assessing the 
outcome of glioblastoma care provided by our institution within the context of being in a 
state with poor health metrics and outcomes. Our principal finding was that glioblastoma 
survival is influenced by patient, tumor, and treatment factors.
We found that an increased age at the time of diagnosis corresponded with decreased 
survival (see figures). The low overall median survival of our patient population may be 
explained by the fact that the majority of them were above 60 years at the time of diagnosis 
(Table 1). Our finding of a low median and 1-year survival in the elderly group corroborates 
other studies which also find a low median survival of 4–6 months in this population, 
sometimes even with standard treatment14,21. In such cases, attention shifts towards 
maintaining a good quality of life. It is, however, noted that these patients still face many 
morbidities13.
As it determines the patient’s responsiveness to treatment with TMZ, we surveyed the 
survival of patients with MGMT methylation. Our findings that MGMT methylation 
increased survival (see figures) are in line with other studies that have found MGMT 
methylation to be a strong prognostic factor10,15 although this is not universal20. Other 
markers such as epidermal growth factor receptor6, alkylpurine-DNA-N-glycosylase 1, 
isocitrate dehydrogenase 124, alpha thalassemia/mental retardation syndrome X-linked 7, 
and p5323 may be tested and have independent and dependent prognostic implications, but 
none of these helps determine a treatment modality.
Since multifocality may influence the risk of undergoing GTR, we looked at the survival of 
patients with using this variable. Most (81%) of patients presented with unifocal tumors. 
When patients presented with multifocal tumors, the approach used was to target the 
resection to the larger tumors evident on imaging and attempt to remove easily accessible 
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nodules within their vicinity. We found an increased median survival in patients with 
unifocal tumors on presentation (see figures), which may be due to anatomic difficulties in 
achieving GTR or due to a different biological behavior of these tumors.
Resection clearly improved survival over biopsy (see figures). When performed as the sole 
intervention, a biopsy was done when the patient was elderly and likely to face further 
morbidity as a result of the surgery or when the tumor was in a deep location that made 
resection dangerous. For our analyses, we considered any resection ≥ 98% to be GTR. GTR 
significantly increases survival over STR as there is a decreased chance of recurrence; 
indeed, most of our recurrences were in patients who had initial subtotal resections. 
Unfortunately, GTR is not possible when the chance of injury to eloquent areas is high. Our 
findings support many studies that have found GTR to be a strong prognostic factor18,22. 
These studies also suggest that resection of the surrounding FLAIR (fluid attenuated 
infusion recovery) signal may also be beneficial.
Completion of the recommended Stupp protocol improved survival (see figures). It is 
important to note the Stupp protocol calls for the use of concurrent TMZ with 54-63Gy 
radiation AND six cycles of post-radiation TMZ; the group that did not complete their 
therapy consisted of those who did not adhere to both requirements. Radiation doses 
prescribed by the neuro-onclogist depended on age and need for aggressive treatment. 
Reasons for not completing the Stupp protocol or forgoing it altogether include a decision to 
go into palliative care, lack of insurance, worsening morbidity, and an assessment by the 
neuro-oncologist that radiation would provide no benefit. Again, here, treatment is focused 
on enhancing quality of life.
In agreement with the literature, the highest survival in our patient population was seen in 
the group that received GTR and adhered to the Stupp protocol (see figures). Predictably, the 
group that underwent STR and adhered to the Stupp protocol had a lower survival. Both 
figures suggest that GTR and the Stupp protocol greatly augment each other.
Our comparison with Julbilirer’s study16 shows that the standard management for 
glioblastoma – GTR with completion of the Stupp protocol – has indeed improved median 
survival in West Virginia (Table 2). This comparison further highlights that overall median 
survival has indeed not increased, even with the implementation of the Stupp protocol, use 
of new modalities, research, and advents in technology. As the interventions involving GTR 
resulted in increased survival in our patients, the lack of an increased overall survival may be 
due to the large number of biopsies we perform as the sole intervention. A possible reason 
for the prevalence of biopsies among our patients may be a reasonable reluctance to subject 
the elderly and those that present with low Karnofsky Performance Scale (KPS) scores to 
resection, a trend that is also present at other institutions21. However, a study by Marina et al 
found that conventional therapy19 – or at least STR28 – does improve survival and functional 
outcomes in elderly patients.
We discovered that the three factors that yielded a median survival at or above the reported 
value of 14.6 months were receiving GTR (regardless of post-surgical interventions), 
adhering to the Stupp protocol (regardless of surgical intervention) and undergoing a 
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treatment course of GTR followed by the Stupp protocol. Our results highlight the fact that 
multiple conditions/interventions differently influence the survival of a patient with 
glioblastoma and that survival has to be considered by the neurosurgeon using such a 
multifactorial stance. Currently, with a median survival of 7 months, we acknowledge that 
there are deficiencies in care (patient and disease factors notwithstanding) even with 
standard interventions being available, which may well stem from outside the hospital 
setting. We may increase the survival in our patient population by having discussions 
through which patients understand the disease process and treatments available and in which 
we advocate (when safe) for the best treatment course – GTR followed by full concurrent 
chemoradiation and post-radiation TMZ. We will also work with patients and other members 
of the healthcare team to ensure both that patients have access to – and follow up with – 
appropriate and timely aspects of standard care.
Unique challenges that patients in West Virginia and the rest of rural Appalachia face in 
attaining optimal care for glioblastoma may include low health literacy4, sparse distribution 
of tertiary care centers, resigned attitudes to terminal illness, and lack of social and family 
support. In a future study, we will identify sociodemographic factors (cultural views, 
income, education, insurance et al) which negatively affect survival with glioblastoma 
among patients in West Virginia. Some limitations of this study stem from its retrospective 
nature that covers patients over a period of 7 years. Firstly, we have added many treatment 
tools since the earliest diagnosis were recorded, which was in 2009. We also have also not 
accounted for advances in training and management protocols and changes in personnel that 
have occurred since then. Secondly, our molecular marker analysis is limited to MGMT as 
other markers were not routinely tested for in the earlier part of this study; until the WHO 
2016 classification made isocitrate dehydrogenase testing routine, we only ordered this test 
when necessary for diagnosis. We now order IDH and MGMT testing routinely, as well as 
newer clinically relevant markers when appropriate, but the number of these newer markers 
is too low for to allow analysis.
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1. An age of diagnosis under 60 years, having the MGMT gene methylated, 
having a unifocal tumor, receiving gross total resection (GTR), adhering to 
the Stupp protocol, and undergoing a treatment course of GTR followed by 
the Stupp protocol significantly increased survival among patients in West 
Virginia
2. Despite much advances in glioblastoma management, median survival of 
patients in West Virginia has not increased since 1996. However, all 
interventions involving GTR have significantly enhanced survival since then. 
The fact that median survival has not increased warrants further investigation.
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Bar graphs showing median survival in months, with SE, according to prognostic indicators 
of survival: a) age at diagnosis; b) MGMT methylation status; c) number of lesions; d) 
surgical intervention; e) completion of the Stupp protocol; f) treatment course
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Kaplan Meier curves of cumulative probability of survival over time according to: a) age at 
diagnosis; b) MGMT methylation status; c) number of lesions; d) surgical intervention; e) 
completion of the Stupp protocol; f) treatment course
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Table 1
Demographic, treatment, and survival information of patients treated for glioblastoma. CRT = chemoradiation, 
GTR = gross total resection, STR = subtotal resection
Number of patients Percentage of patients Number of long- term survivors
Gender
 Male 147 60.5
 Female 96 39.5
Age at diagnosis
 20–59 98 40.3 14
 ≥60 145 59.7 4
Surgical technique useda
 Biopsy alone 70 52.6 0
 STR 27 20.3 2
 GTR 36 27.1 7
 Re-resection 50/125 40.0
Completion of the Stupp protocolb
 Full 67 60.4 10
 Incomplete 26 23.4 0
 None 18 16.2 0
 Survival (m)
 <1 17 7.0
 1–12 143 58.8
 13–24 46 18.9
 25–36 19 7.8
 37–48 6 2.5
 >48 12 4.9
a
some patients did not have post-operative imaging and thus could not be definitely classified as having received STR or GTR
b
adherence to the Stupp protocol could not be determined for some patients treated at other institutions
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Table 2
Summary of interventions and outcomes between our current study and Jubilirer’s 1996 study at CAMC. “RT” 
should be taken to mean “Stupp protocol” in the context of WVUH. CAMC: Charleston Area Medical Center, 
CI: Confidence interval, GTR: Gross total resection, RT: radiation therapy, STR: Subtotal resection, WVUH: 
West Virginia University Hospitals
WVUH CAMC
Number of patients 243 138
Median age at diagnosis (range) 63 (20–88) 59 (21–87)
Percentage of females 39.5 42
Overall median survival (95% CI) 7 (6–10) 7
Percentage receiving GTR 27.1 29
Survival with GTR (95% CI) 15 (10–25) 4 (2–6)
Percentage receiving GTR and RT 11.2 23.9
Survival with GTR and RT (95% CI) 23.5 (12–37) 12 (10–13)
Percentage receiving STR 20.3 26.1
Survival with STR (95% CI) 10 (3–15) 3 (1–7)
Percentage receiving STR and RT 6.0 18.8
Survival with STR and RT (95% CI) 14 (3–16) 10 (7–14)
Percentage receiving biopsy 52.6 2.2
Percentage receiving RT 73 42.7
1-year survival (%) 36.6 29
2-year survival (%) 15.4 3
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